Investigating a specific RNA's role in a type of lymphoma linked to AIDS
Official title: Role of a latent OriLyt RNA in KSHV latency in primary effusion lymphoma
Funded at Univ of Arkansas for Med Scis · NIH-10896992 · Data updated 2026-11-12
This study is looking at how a specific RNA helps certain cancer cells survive, which could lead to new treatments for people with primary effusion lymphoma linked to a virus.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Arkansas for Med Scis NIH-funded |
| Lab location | 1 site (Little Rock, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $178,819 |
| NIH project number | 5R21CA285135-02 |
| Project ID | NIH-10896992 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with primary effusion lymphoma or those who are KSHV-positive and experiencing related health issues.
✕Less likely to help
Patients with other types of lymphomas or those not infected with KSHV may not benefit from this research.
What this research studies
This research focuses on understanding how a particular RNA, known as OriLyt, contributes to the survival of primary effusion lymphoma (PEL) cells, which are associated with Kaposi's sarcoma-associated herpesvirus (KSHV). The study employs advanced techniques like RNA-targeting CRISPR/CasRx to identify viral factors essential for the growth of these cancer cells. By analyzing the expression of latency genes and their role in maintaining the cancer cells, the research aims to uncover critical insights that could lead to new treatment strategies for patients affected by this malignancy.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating primary effusion lymphoma, potentially improving outcomes for patients.
How similar studies have gone: Other research has shown promise in targeting viral factors in cancer treatment, suggesting that this approach could yield significant insights.
Where this research is happening
-
Univ of Arkansas for Med Scis
Little Rock, United States Active
Researchers
- Principal investigator: Manzano, Mark — Univ of Arkansas for Med Scis
- Study coordinator: Manzano, Mark
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.